FDMT Stock Overview
A clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States.
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 2/6 |
Past Performance | 0/6 |
Financial Health | 5/6 |
Dividends | 0/6 |
4D Molecular Therapeutics, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$11.90 |
52 Week High | US$36.25 |
52 Week Low | US$9.44 |
Beta | 2.79 |
11 Month Change | -21.66% |
3 Month Change | -48.13% |
1 Year Change | -14.45% |
33 Year Change | -66.17% |
5 Year Change | n/a |
Change since IPO | -70.62% |
Recent News & Updates
4D Molecular Therapeutics (NASDAQ:FDMT) Is In A Good Position To Deliver On Growth Plans
Aug 104D Molecular Therapeutics: R100 Vector Pushes Forward To Bring Q4 Of 2024 DME Data
Jul 19Recent updates
4D Molecular Therapeutics (NASDAQ:FDMT) Is In A Good Position To Deliver On Growth Plans
Aug 104D Molecular Therapeutics: R100 Vector Pushes Forward To Bring Q4 Of 2024 DME Data
Jul 194D Molecular Therapeutics: Catalysts With Pioneering Gene Therapy With Directed Evolution
Apr 294D Molecular Therapeutics Advances Wet AMD Treatment Paradigm
Feb 064D Molecular Therapeutics: Several Value Inflection Points To Watch In 2024
Jan 254D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Just Reported And Analysts Have Been Cutting Their Estimates
Nov 12We're Not Very Worried About 4D Molecular Therapeutics' (NASDAQ:FDMT) Cash Burn Rate
Nov 08Here's Why We're Watching 4D Molecular Therapeutics' (NASDAQ:FDMT) Cash Burn Situation
May 08We're Keeping An Eye On 4D Molecular Therapeutics' (NASDAQ:FDMT) Cash Burn Rate
Sep 294D Molecular Therapeutics GAAP EPS of -$0.87, revenue of $0.16M
Aug 11Here's Why We're Watching 4D Molecular Therapeutics' (NASDAQ:FDMT) Cash Burn Situation
Jun 11We're Hopeful That 4D Molecular Therapeutics (NASDAQ:FDMT) Will Use Its Cash Wisely
Aug 06Newsflash: 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Analysts Have Been Trimming Their Revenue Forecasts
Jun 28Shareholder Returns
FDMT | US Biotechs | US Market | |
---|---|---|---|
7D | -26.8% | 1.4% | 2.6% |
1Y | -14.5% | 23.1% | 30.5% |
Return vs Industry: FDMT underperformed the US Biotechs industry which returned 23.1% over the past year.
Return vs Market: FDMT underperformed the US Market which returned 30.5% over the past year.
Price Volatility
FDMT volatility | |
---|---|
FDMT Average Weekly Movement | 15.1% |
Biotechs Industry Average Movement | 10.1% |
Market Average Movement | 6.3% |
10% most volatile stocks in US Market | 15.0% |
10% least volatile stocks in US Market | 3.1% |
Stable Share Price: FDMT's share price has been volatile over the past 3 months.
Volatility Over Time: FDMT's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2013 | 201 | David Kirn | www.4dmoleculartherapeutics.com |
4D Molecular Therapeutics, Inc., a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology. Its product pipeline includes 4D-150, which is in phase 1/2 clinical trial for the treatment of wet age-related macular degeneration; and is in phase 1/2 clinical trial for the treatment of diabetic macular edema.
4D Molecular Therapeutics, Inc. Fundamentals Summary
FDMT fundamental statistics | |
---|---|
Market cap | US$701.59m |
Earnings (TTM) | -US$109.89m |
Revenue (TTM) | US$20.22m |
30.6x
P/S Ratio-5.6x
P/E RatioIs FDMT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
FDMT income statement (TTM) | |
---|---|
Revenue | US$20.22m |
Cost of Revenue | US$110.82m |
Gross Profit | -US$90.60m |
Other Expenses | US$19.29m |
Earnings | -US$109.89m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | -2.11 |
Gross Margin | -448.13% |
Net Profit Margin | -543.54% |
Debt/Equity Ratio | 0% |
How did FDMT perform over the long term?
See historical performance and comparison